A Long-term Follow-up Study in Patients Who Received BEAM-101
← catalyst calendarNCT07373639 · readout in 6,021 d
Sponsored by Beam Therapeutics Inc. (industry) · BEAM — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | 2043-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2043-02-12 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hemoglobinopathy
- Sickle Cell Disease
Intervention
- Drug: Long-Term Follow-up Study of patients who received BEAM-101
Primary outcome
what the primary-completion date above is the date OFLong-Term Safety Monitoring and Mortality Assessment
measured Up to 13 years
Permalink · BEAM's whole pipeline · Catalyst calendar · Every registered study · What changed